Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. (original) (raw)
Research Article Free access | 10.1172/JCI118892
Department of Medicine, The University of Alabama at Birmingham 35294, USA.
Find articles by Wu, J. in:JCI |PubMed |Google Scholar
Department of Medicine, The University of Alabama at Birmingham 35294, USA.
Find articles by Wilson, J. in:JCI |PubMed |Google Scholar
Department of Medicine, The University of Alabama at Birmingham 35294, USA.
Find articles by He, J. in:JCI |PubMed |Google Scholar
Department of Medicine, The University of Alabama at Birmingham 35294, USA.
Find articles by Xiang, L. in:JCI |PubMed |Google Scholar
Department of Medicine, The University of Alabama at Birmingham 35294, USA.
Find articles by Schur, P. in:[JCI](/search/results?q=author.first%5Fname%3A%22P H%22+author.last%5Fname%3A%22Schur%22&search%5Ftype=advanced) |PubMed |Google Scholar
Department of Medicine, The University of Alabama at Birmingham 35294, USA.
Find articles by Mountz, J. in:[JCI](/search/results?q=author.first%5Fname%3A%22J D%22+author.last%5Fname%3A%22Mountz%22&search%5Ftype=advanced) |PubMed |Google Scholar
Published September 1, 1996 -More info
Published September 1, 1996 -Version history
The pathogenesis of systemic lupus erythematosus (SLE) is multifactorial and multigenetic. The apoptosis genes, fas and fas ligand (fasL), are candidate contributory genes in human SLE, as mutations of these genes result in autoimmunity in several murine models of this disease. In humans, fas mutations result in a familial autoimmune lymphoproliferative syndrome, but defects in FasL have not yet been identified. In this study, DNA from 75 patients with SLE was screened by single-stranded conformational polymorphism analysis for potential mutations of the extracellular domain of FasL. A heterozygous single-stranded conformational polymorphism for FasL, was identified in one SLE patient, who exhibited lymphadenopathy. Molecular cloning and sequencing indicated that the genomic DNA of this patient contained an 84-bp deletion within exon 4 of the fasL gene, resulting in a predicted 28 amino acid in-frame deletion. Analysis of PBMC from this patient revealed decreased FasL activity, decreased activation-induced cell death, and increased T cell proliferation after activation. This is the first report of defective FasL-mediated apoptosis related to a mutation of the human Fasl, gene in a patient with SLE and suggests that fasL mutations are an uncommon cause of the disease.
- Version 1 (September 1, 1996): No description